Pharmaceuticals

C-Ray Therapeutics and SHINE Technologies Enter Strategic Partnership for Exclusive Distribution of No-Carrier-Added Lu-177 in Mainland China

CHENGDU, China and JANESVILLE, Wis., March 26, 2026 /PRNewswire/ -- C-Ray Therapeutics (Chengdu, China), a global radiopharmaceutical CRDMO, today announced the execution of aMaster Radioisotope Supply Agreement with SHINE Technologies, LLC (Janesville, Wisconsin, USA), establishing a long-term, ...

2026-03-26 20:53 4275

Samsung Biologics Recognized for Advancing Sustainability at 2026 CDMO Leadership Awards

* Reinforcing long-term commitment to embedding sustainability across operations and partnerships * Continuing to support clients in delivering high-quality, life-saving medicines to patients worldwide INCHEON, South Korea, March 26, 2026 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a ...

2026-03-26 20:00 4924

Chula, Thai Red Cross Society Partner to Bring "SALYWA" Artificial Saliva to Patients

BANGKOK, March 26, 2026 /PRNewswire/ -- Chulalongkorn University , in collaboration with the Thai Red Cross Society  and Specialty Innovation Co., Ltd., held a press conference announcing the licensing agreement for research utilization a...

2026-03-26 18:04 4673

Innovent Announces 2025 Annual Results and Business Updates

From China Leadership to Global Premier: Revenue Surpasses RMB 10 Billion, Entering the Era of Profitability and Globalization SAN FRANCISCO and SUZHOU, China, March 26, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develop...

2026-03-26 18:00 7199

GC Biopharma Receives Marketing Authorization for Varicella Vaccine 'BARYCELA Inj.' in Guatemala

- First regulatory clearance in Latin America marks a strategic milestone for regional market expansion - World's first antibiotic-free manufacturing process ensures superior safety profile YONGIN, South Korea, March 26, 2026 /PRNewswire/ -- GC Biopharma(006280.KS), a leading provider of biophar...

2026-03-26 14:23 3837

Alphamab Oncology Reports Full Year 2025 Financial Results and Business Highlights

SUZHOU, China, March 26, 2026 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) reported financial results for the full year ended December 31, 2025 and highlighted recent business progress. Key Highlights * KN026 (Anbenitamab) achieved robust PFS and OS benefits in second- or third-lin...

2026-03-26 13:13 7030

Hengrui Pharma Announces Strong 2025 Annual Results

SHANGHAI, March 25, 2026 /PRNewswire/ -- On March 25, 2026, Hengrui Pharma (600276.SH; 01276.HK) announced robust financial results for the full year 2025, fueled by its dual strategy of innovation and globalization. Revenue increased 13% year-on-year to RMB 31.63 billion, and net profit attribut...

2026-03-26 08:52 4456

Clarity signs a large-scale Manufacturing Supply Agreement for copper-64 with Theragenics

SYDNEY, March 25, 2026 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce the signing of a lar...

2026-03-25 21:01 5341

Alteogen Enters into a License Agreement with Biogen for Development and Commercialization of Hybrozyme™-Based Subcutaneous Biologics

- Biogen gains rights to develop and commercialize subcutaneous (SC) formulations for two products utilizing ALT-B4 DAEJEON, South Korea, March 25, 2026 /PRNewswire/ -- Alteogen Inc. (KOSDAQ: 196170) announced today that it has entered into an exclusive license agreement with Biogen Inc. for the...

2026-03-25 20:00 4333

LakeShore Biopharma Announces Receipt of a Revised Preliminary Non-Binding Proposal to Acquire the Company

BEIJING, March 25, 2026 /PRNewswire/ -- LakeShore Biopharma Co., Ltd ("LakeShore Biopharma" or the "Company") (OTCPK: LSBCF; OTCPK: LSBWF), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics ...

2026-03-25 20:00 5072

HanchorBio Advances Toward TWSE Innovation Board Listing to Accelerate Global Clinical Development, Platform Expansion, and International Partnering

Listing milestone positions HanchorBio to strengthen institutional visibility, advance itsFBDB™ platform, and expand a growing pipeline spanning oncology and broader immune-mediated diseases TAIPEI, SHANGHAI and SAN FRANCISCO, March 25, 2026 /PRNewswire/ -- HanchorBio, Inc. (TPEx: 7827), a globa...

2026-03-25 18:00 4337

VERIGRAFT Advances First Potential Curative Treatment for CVI into Pivotal Phase II/III Trial

* Pivotal Phase II/III clinical trial underway, aiming for US and European market approval in 2028 * A 'truly transformative' regenerative medicine targeting a multi-million patient population with no existing curative treatment * Fully biological transplant eliminates need for immunosuppres...

2026-03-25 17:11 3669

BrightGene Announces Positive Topline Phase 1 Results of Oral BGM0504 in Obesity in China and the United States

BGM0504 shown to be generally well tolerated Overall safety, pk, and efficacy profile supports once-daily oral dosing SUZHOU, China, March 25, 2026 /PRNewswire/ -- BrightGene Bio-Medical Technology Co., Ltd. (SSE: 688166, "BrightGene" or "the Company") today announced positive topline results f...

2026-03-25 14:32 4107

Akeso Advances "IO 2.0 + ADC 2.0" Strategy with Phase II Initiation of Novel ADCs Combined with Ivonescimab and Cadonilimab

HONG KONG, March 24, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK)  ("Akeso" or the "Company") announced today that it has received clearance from the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) to initiate Phase II clinical trials for AK146D1, a first...

2026-03-25 10:40 5159

Hope Medicine Announces First Patient Dosed in the Phase III Clinical Trial for Endometriosis

SHANGHAI, March 24, 2026 /PRNewswire/ -- Hope Medicine Inc., a science-driven, clinical-stage innovative biopharmaceutical company, announced that the first patient has been dosed in the Phase III clinical trial of HMI-115, its first-in-class monoclonal antibody with global rights, for the treatm...

2026-03-25 08:08 5111

Fosun Pharma Announces 2025 Annual Results

Innovation and Globalization Propel Fosun Pharma's High-Quality Growth SHANGHAI, March 24, 2026 /PRNewswire/ -- On 24 March, 2026, Fosun Pharma ("the company", stock code: 600196.SH; 02196.HK), an innovation-driven global pharmaceutical and healthcare group, announced its 2025 annual operating r...

2026-03-24 22:47 4729

BIOTRONIK Leaps Forward with Next‑Generation Leadless Pacing

* International BIO-LivIQ Study Will Generate Evidence for Global LivIQ Leadless Pacemaker Approvals * Far-Field Sensing and AV-Synchronous Pacing Performance Will be Validated by Real World Clinical Data BERLIN, March 24, 2026 /PRNewswire/ -- BIOTRONIK today announced the initiation of its g...

2026-03-24 22:06 2984

HKeyBio Launches HKEY-NHP-onChip™ 1.1: World's First NHP In Vitro Model for Autoimmune and Allergic Diseases

The integrated organ-on-chip platform offers 10–100x cost efficiency and 80% reduction in animal use, bridging the gap between preclinical NHP research and human clinical success. SUZHOU, China, SAN FRANCISCO and BOSTON, March 24, 2026 /PRNewswire/ -- HKeyBio, a global leading CRO specializing in...

2026-03-24 20:30 3282

Insilico Medicine and ASKA Pharmaceutical Expand Partnership to Discover Novel Targets for Women's Health

CAMBRIDGE, Mass., March 24, 2026 /PRNewswire/ -- Insilico Medicine (3696.HK), a clinical-stage drug discovery and development company driven by generative artificial intelligence (AI), today announced a strategic research collaboration with ASKA Pharmaceutical Co., Ltd. ("ASKA"), a specialized p...

2026-03-24 18:29 3717

GCCL Showcases RSV FRNT Research and Integrated Bioanalytical Capabilities at World Vaccine Congress 2026

YONGIN, South Korea, March 24, 2026 /PRNewswire/ -- GCCL Co., Ltd. (GCCL), a global clinical trial laboratory services provider, announced that it will attend World Vaccine Congress 2026 (WVC 2026), taking place from March 30 to April 2 in Washington, D.C., where it will operate an exhibition boo...

2026-03-24 17:35 3417
1 ... 9101112131415 ... 342

Week's Top Stories